Our biomarker tests

OncoDEEP^® Kit

Our knowledge in your hands

Cancer type:

Starting material:

Gene panel:

Genomic signatures:

Capture method:

Kit Content:

Pan solid tumors

Tumor tissue (DNA + RNA)

600+

HRD, TMB, MSI, LOH

Twist Bioscience

Reagents + Data Analysis + Reporting

Request more information

What Is OncoDEEP Kit?

An end-to-end workflow solution for comprehensive genomic profiling of tumor tissues

OncoDEEP Kit is an integrated solution that combines a pan-cancer NGS assay and bioinformatics tools for the in-house comprehensive biomarker testing of tumor tissues. The OncoDEEP Kit panel targets DNA and RNA across over 600 genes, assessing biomarkers associated with the latest cancer drugs and clinical trials available for solid tumors. It also measures complex genomic signatures, such as homologous recombination deficiency (HRD), microsatellite instability (MSI), tumor mutational burden (TMB), and loss of heterozygosity (LOH).

OncoDEEP Kit provides a complete solution for laboratories willing to enhance their NGS efforts and to adopt comprehensive biomarker testing in house. With this offering, even laboratories with limited bioinformatics capabilities have the combined ability to profile a large number of cancer biomarkers and assess complex biomarkers in a single test. Combined with OncoDNA bioinformatics software tools, OncoDEEP Kit will enable you to identify a broader set of treatment options for patients, while saving on time and cost of outsourcing.

Laboratory workflow

Integrated Solution

Tumor slides are analyzed with NGS and immunohistochemistry for cancer biomarker testing

Discover the molecular profile of a tumor

Thanks to biomarker testing, it is now possible to examine the therapeutic vulnerabilities of an individual tumor. Running one single comprehensive test is often cheaper and faster than deploying multiple tests on small genomic panel. It is also less likely to exhaust a tumor tissue biopsy. OncoDEEP^® offers a unique combination of molecular diagnostic and genomic profiling tests that target a large NGS panel of over 600 genes and tumor-specific biomarkers. The test is accurate and robust. It screens for genomic alterations (DNA & RNA), genomic signatures (MSI, TMB, HRD) and protein biomarkers of response to targeted therapies, immunotherapies, hormone therapy and chemotherapy.

Oncologist reads cancer treatment recommendations on OncoSHARE

Obtain patient-specific clinical recommandations

OncoDEEP^®comes with a clinical interpretation of the complex genomic and molecular data. The clinical recommendations are supported by OncoDNA’s proprietary curated database that matches your patient’s tumor profile with relevant therapeutic options. Our database is kept up to date and daily screens for the latest therapeutic advances in precision oncology. The results will be made available in less than two weeks on OncoSHARE, our secure web-based platform. On OncoSHARE, you will be able to visualize your personalized report and download it in PDF format from anywhere in the world. The platform connects healthcare professionals with whom you can discuss the various clinical scenarios through virtual meetings and tumor boards.

Healthcare providers hold hands as mark of collaboration

Benefit from scientific quality support

Our scientific support teams are at hand to assist you every step of the way:

1) Test evaluation and benefits for your patient

2) Sample preparation and collection based on our protocol

3) Sample QC check performed by our pathologist

4) Sample analysis by ISO15189 accredited and CLIA and CAP certified laboratories

5) Interpretation of the complex genomic and biomarker data into clear clinical recommendations

6) Interactive report available on our secure OncoSHARE platform

Why Choose OncoDEEP Kit?

From reagents to clinical reporting

OncoDEEP Kit offers an end-to-end workflow solution to easily adopt CGP in your lab and achieve reliable results.

Obtain a complete kit with all material and documentations to guide you at every step.
Achieve superior efficiency with Twist Bioscience's library preparation, pooling and capture methods.
Save time and optimize the accuracy of your lab operations with automation protocols.
Analyze the data and access extensive quality controls utilizing MERCURY, OncoDNA’s proprietary cloud-based software tool.

All biomarkers in one test

The OncoDEEP panel includes 600+ biomarkers carefully selected for their clinical relevance in oncology.

Save time and cost of running multiple individual biomarker tests
Analyze fusion genes, unusual splicing, and measure complex genomic signatures
Increase chances of identifying actionable biomarkers
Extend treatment options to investigational new drugs and oncology clinical trials

Flexibility and control

Dig deep into the raw data, analyze the detail and run extensive quality controls utilizing MERCURY™, OncoDNA’s proprietary cloud-based software tool.
Save your data in a secure cloud-based software.
Personalize the online visualization as well as thresholds and analysis parameters of the data on MERCURY.
Export the results into various formats, from VCF files for upload into your LIMS to clinical reports for oncologists.
Go one step further and obtain patient-specific clinical interpretation reports on OncoKDM.

What Do Experts Say?

We see biomarkers such as HRD and MSI play an increasingly essential role in precision medicine, however, the development and validation of the pan-cancer bioanalytical methods remain burdensome. With its OncoDEEP kit, OncoDNA provides us with the appropriate tools to analyze such complex biomarkers. I feel confident that it will help us access critical insights to drive precision medicine.

Koen Jacobs

Molecular Biologist, AZ Sint-Lucas Gent

FAQs

What does OncoDEEP Kit include?

OncoDEEP Kit includes all the materials required to perform the comprehensive biomarker testing of solid tumors. The Kit comes with the reagents and probes associated with Twist Capture technology, as well as with the bioinformatics pipeline and our secure, cloud-based MERCURY software to analyze the raw data and access extensive quality control tools. OncoDNA also offers the opportunity to run the sequencing data through its proprietary database and extract patient-specific clinical interpretation reports made available on its OncoKDM online platform. To date, its database counts no less than 4,500,000 genetic variants, 1,150 cancer drugs, and data from 7,000 clinical trials.

How do you calculate the HRD score?

Comprehensive biomarker testing - also known as comprehensive genomic profiling or genomic cancer test or molecular diagnostic test - is a next-generation sequencing (NGS) approach that uses a single assay to detect relevant cancer biomarkers, alterations in genes that are known to drive cancer growth, as established in guidelines and clinical trials, for therapy guidance. OncoDEEP® goes one step further by integrating tumor-specific biomarker analyses to maximize the clinical benefit for the patients.

Is RNA seq included in OncoDEEP Kit?

Laboratories will have the opportunity to select two types of OncoDEEP Kit: one kit for DNA sequencing only, and another one for the combination of DNA and RNA sequencing.

How many samples can we perform per flowcell?

The OncoDEEP^® comprehensive biomarker test combines NGS with IHC testing to screen for genomic alterations in the DNA and RNA (BRCA mutation, KRAS mutation, EGFR mutations, etc), genomic signatures (tumor mutational burden, homologous recombination deficiency and microsatellite instability testing) and protein biomarkers of response to targeted therapies, immunotherapy, hormonal therapy and chemotherapy. The technology is robust and accurate, and the genes of the panel were carefully selected based on their biological and therapeutical relevance.

Which variants can be detected through the OncoDEEP Kit?

OncoDEEP^® can be used at diagnosis or at disease progression to identify biomarker-matched targeted therapies or biomarker-stratified clinical trials. It can also provide physicians with extra therapeutic guidance when chemotherapy does not work; when new biomarkers are required for second-line treatment; when cancer comes back; or when patients are diagnosed with highly aggressive cancer or a rare cancer type like a cancer of unknow primary.

Is OncoDEEP Kit accredited and certified?

The ISO 15189 (Medical laboratories-Requirements for quality and competence), CE-IVD (In vitro diagnostic devices complied to be sold in Europe), ISO 27001 (Information security management) and ISO 13485:2016 (Quality Management System) apply to our OncoDEEP^® comprehensive biomarker test.

Can we run an OncoDEEP Kit on blood samples?

Ordering a solution is very simple: Just log in to OncoSHARE and select the biomarker test(s) you are interested in. If you do not have a kit for the collection of the FFPE tissue sample, we will send you one.

How long does it take to receive an OncoDEEP Kit?

It takes about 10 working days from the FFPE tissue sample quality control check to reporting on our clinical decision support system.

What is the price of an OncoDEEP Kit?

For information regarding the price of our OncoDEEP^® biomarker test in your respective country, please contact our sales team.

Cannot find what you are looking for? Contact us! Our Scientific Support Teams are available to answer all your questions from Monday to Friday.